Oncology: International Journal of Cancer Research and Treatment
Fecha de publicación: April 2020
Autores: Blanter J., Zimmerman B., Tharakan S., Ru M., Cascetta K., Tiersten A.b
Background: The Oncotype DX Breast Cancer Assay is a 21-gene assay used to predict the likelihood of distant recurrence and the benefit of chemotherapy in patients with node-negative, tamoxifen-treated breast cancer. Prior studies demonstrated 7–19% discordance, or a difference between the recurrence score (RS) and tumor grade (TG) in breast cancer patients. BRCA mutated tumors (BRCA+) have been shown to be associated with higher RS as compared to BRCA-negative patients (BRCA–).